SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the ...
Almirall SA has submitted a CTA filing for a bispecific antibody targeting IL-13 and OX-40L for the treatment of atopic dermatitis. The company expects to initiate a first-in-human phase I trial ...
The federal government in a court brief continued to defend the constitutionality of the Corporate Transparency Act (CTA), P.L. 116-283, even though the government has, at least temporarily, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results